| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 31, 2026 | Datroway approved in EU for TNBC | Datroway approved in EU for TNBC
Fri, Jul 31, 2026 08:48 CET Report this content
31 July 2026
Datroway approved in the EU as only TROP2-directed medicine with overall survival benefit for the 1st-line treatment of patients with metastatic T... |
| Jun 29, 2026 | Datroway recommended for approval in EU for TNBC | Datroway recommended for approval in EU for TNBC
Mon, Jun 29, 2026 08:00 CET Report this content
29 June 2026
Datroway recommended for approval in the EU by CHMP as 1st-line treatment for patients with metastatic triple-negative breast canc... |
| Jun 15, 2026 | Truqap approved in US for prostate cancer | Truqap approved in US for prostate cancer
Mon, Jun 15, 2026 08:00 CET Report this content
15 June 2026
Truqap combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cance... |
| May 26, 2026 | Datroway approved in US for 1L triple-negative BC | Datroway approved in US for 1L triple-negative BC
Tue, May 26, 2026 08:00 CET Report this content
26 May 2026
Datroway approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic tri... |
| May 18, 2026 | Enhertu approved in two HER2+ early BC settings | Enhertu approved in two HER2+ early BC settings
Mon, May 18, 2026 08:05 CET Report this content
18 May 2026
Enhertu approved in the US for two new indications for patients with HER2-positive early breast cancer
Approved for use before surge... |
| May 1, 2026 | FDA ODAC vote on camizestrant in breast cancer | FDA ODAC vote on camizestrant in breast cancer
Fri, May 01, 2026 08:05 CET Report this content
01 May 2026
Update on FDA Advisory Committee vote on camizestrant in combination with a CDK4/6 inhibitor for advanced HR-positive breast cancer
T... |
| May 1, 2026 | FDA ODAC recommends Truqap in prostate cancer | FDA ODAC recommends Truqap in prostate cancer
Fri, May 01, 2026 08:00 CET Report this content
01 May 2026
Truqap recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer
ODAC overwhelming majorit... |
| Mar 20, 2026 | AI tool helps diagnose an often-misclassified group of rare thymic tumors | A team led by researchers at the University of Chicago developed an artificial intelligence (AI) tool that could help pathologists more accurately diagnose a rare group of tumors known as thymic epithelial tumors (TETs). The work is describ... |
| Feb 18, 2025 | Dignitana's Expanding Reach: A New Era for Cancer Care in Romania and Beyond | Dignitana is on the move. The Swedish company, known for its innovative scalp cooling technology, has taken a significant step in expanding its global footprint. Recently, it announced a partnership with Chronos Trade Medical, making them t... |
| Feb 17, 2025 | Chronos Trade Medical joins Dignitana as exclusive distributor in Romania | Chronos Trade Medical joins Dignitana as exclusive distributor in Romania
Mon, Feb 17, 2025 08:08 CET Report this content
Dignitana has signed a Distribution Agreement for Chronos Trade Medical to be the exclusive provider of The DigniCap S... |
| Jan 8, 2025 | Published in Annals of Oncology: Disitamab Vedotin Combined with PD-1 Inhibitor is a Promising Treatment for Locally Advanced or Metastatic Urothelial Carcinoma | YANTAI, China, Jan. 8, 2025 /PRNewswire/ -- On Janurary 7th, 2025, Annals of Oncology (IF: 56.7), a top oncology journal globally, published remarkable long-term follow-up results of a phase 1b/2 clinical trial on Disitamab Vedotin (DV) (de... |
| Dec 12, 2024 | Dignitana signs Boosst as exclusive distributor in Ecuador and Peru | Dignitana signs Boosst as exclusive distributor in Ecuador and Peru
Thu, Dec 12, 2024 14:31 CET Report this content
Dignitana has signed a Distribution Agreement for Boosst to be the exclusive provider of The DigniCap Scalp Cooling System i... |
| May 21, 2024 | Dignitana signs an exclusivity agreement for Japan with Konica Minolta | Dignitana signs an exclusivity agreement for Japan with Konica Minolta
Tue, May 21, 2024 10:03 CET Report this content
Dignitana has signed a new multi-year Distribution Agreement for technology market leader Konica Minolta to be the exclus... |
| Mar 25, 2024 | Dignitana nominated for inaugural Texas Impact Enterprise Awards | Dignitana nominated for inaugural Texas Impact Enterprise Awards
Mon, Mar 25, 2024 15:02 CET Report this content
Dignitana announces that it has been nominated for the inaugural Texas Impact Enterprise Awards. The award recognizes organizat... |
| Mar 7, 2024 | DigniCap Delta study underway in Brindisi, Italy | DigniCap Delta study underway in Brindisi, Italy
Thu, Mar 07, 2024 08:10 CET Report this content
Dignitana announces that Antonio Perrino Hospital in Brindisi, Italy has initiated a clinical study of the DigniCap Delta Scalp Cooling System ... |
| Feb 29, 2024 | Dignitana to exhibit at Onkologidagarna in Malmö | Dignitana to exhibit at Onkologidagarna in Malmö
Thu, Feb 29, 2024 10:39 CET Report this content
Dignitana AB, scalp cooling innovation leader, will present the advanced technology of the DigniCap Delta Scalp Cooling System at Onkologidaga... |
| Feb 12, 2024 | DigniCap Delta receives market approval in Japan | DigniCap Delta receives market approval in Japan
Mon, Feb 12, 2024 09:02 CET Report this content
Dignitana announces that DigniCap Delta received market approval in Japan from the Ministry of Health, Labor and Welfare (MHLW). In Japan, Dign... |
| Feb 2, 2024 | Dignitana convenes Training Academy bringing distributors to Lund Headquarters | Dignitana convenes Training Academy bringing distributors to Lund Headquarters
Fri, Feb 02, 2024 10:00 CET Report this content
Scalp cooling innovator Dignitana AB has brought together MedTech experts from five regions around the globe for ... |
| Jan 16, 2024 | Preliminary results of DigniCap Delta study demonstrate 79 percent efficacy | Preliminary results of DigniCap Delta study demonstrate 79 percent efficacy
Tue, Jan 16, 2024 10:14 CET Report this content
Dignitana announces that the Hospital de Clínicas in Montevideo, Uruguay has completed the first stage of a two-year... |
| Jan 15, 2024 | Dignitana signs OncoMedical for distribution in Switzerland and Liechtenstein | Dignitana signs OncoMedical for distribution in Switzerland and Liechtenstein
Mon, Jan 15, 2024 13:00 CET Report this content
Scalp cooling innovator Dignitana AB has signed OncoMedical AG as the exclusive distributor for The DigniCap Scalp... |
| Oct 4, 2023 | Dignitana announces a sales and marketing partnership with InfuSystem to provide scalp cooling systems in the United States | Dignitana announces a sales and marketing partnership with InfuSystem to provide scalp cooling systems in the United States
Wed, Oct 04, 2023 08:45 CET Report this content
Scalp cooling innovator Dignitana AB announces today a sales and mar... |
| Apr 12, 2023 | Investing in Function Oncology | “The power in tailored therapeutics is for us to say more clearly to payers, providers, and patients: ‘this drug is not for everyone, but it is for you.’ That is exceedingly powerful.” —John C. Lechleiter, Ph.D., former Chairman, President,... |
| Mar 22, 2023 | Dignitana enters Hong Kong market with leading distributor Science International Corporation | Dignitana enters Hong Kong market with leading distributor Science International Corporation
Wed, Mar 22, 2023 08:20 CET Report this content
Scalp cooling innovator Dignitana AB has signed Science International Corporation, a leading distri... |
| Jul 14, 2022 | Study shows that selection of breast cancer patients for adjuvant bisphosphonate therapy based on Inbiomotion’s MAFTEST® reduces the risk of death in comparison with current clinical guidance | Barcelona, July 14 2022; Inbiomotion SL, a company developing a unique single-gene-based biomarker for the personalized adjuvant treatment of early-stage (stage I-III) breast cancer patients, announces the results of comparing the clinical ... |
| Jan 2, 2022 | The 6 most mind-blowing human health discoveries of 2021 | COVID-19 research was just the tip of the iceberg for 2021 discoveries.
Getty Images
There were many important scientific discoveries unrelated to Covid-19 this year.
Scientists have studied and developed new treatments for everything from ... |
| Dec 27, 2021 | The 6 most mind-blowing human health discoveries of 2021 | COVID-19 research was just the tip of the iceberg for 2021 discoveries. Getty Images
There were many important scientific discoveries unrelated to COVID-19 this year.
Scientists have studied and developed new treatments for everything from ... |
| Oct 20, 2021 | Blood tests that can detect cancer are about to hit the market. But experts are still waiting to see if they can upend deadly disease. | A scientist drips blood into a test tube. Serhii Hudak/ Ukrinform/Barcroft Media via Getty Images
Two companies – Exact Sciences and Illumina – plan to have blood tests that detect cancer available by 2022.
They have spent a combined $US10.... |
| Sep 30, 2021 | AI improves precision in breast cancer diagnosis | AI improves precision in breast cancer diagnosis Thu, Sep 30, 2021 01:05 CET
Researchers at Karolinska Institutet in Sweden have developed an AI-based tool that improves the diagnosis of breast cancer tumours and the ability to predict the ... |
| Jul 29, 2021 | Dignitana signs distributor B&Co Group to support Benelux Growth | Dignitana signs distributor B&Co Group to support Benelux Growth Thu, Jul 29, 2021 15:21 CET
Dignitana, world leader in scalp cooling innovation, has signed with leading distributor B&Co Group to drive growth in the Benelux region. ... |
| May 11, 2021 | Illumina CEO insists GRAIL merger will be good for competition, and ultimately, patients | Before the pandemic, most people had never heard of Illumina, the California-based sequencing behemoth whose machines generate upwards of 90% of the world’s DNA data. And while Illumina might still not be a household name, over the last 15 ... |
| May 4, 2021 | BIOCARTIS GROUP NV
Biocartis : Announces New Collaboration with AstraZeneca to Expand Availability of Idylla™ EGFR Biomarker Testing Among Patients with Lung Cancer | PRESS RELEASE 4 May 2021, 07:00 CEST
Biocartis Announces New Collaboration with AstraZeneca to Expand Availability of Idylla™ EGFR Biomarker Testing Among Patients with Lung Cancer
Approximately half of the patients with non-small cell lung... |
| Jan 13, 2021 | IO Biotech raises $155M to trial IDO and PD-L1 cancer vaccines | IO Biotech has raised €127 million ($155 million) to fund clinical development of immune-modulating IDO and PD-L1 cancer vaccines. The series B financing round comes months after IO Biotech showed combining its IDO and PD-L1 vaccines with O... |
| Jan 7, 2021 | Tumor Mutational Burden: A Continually Evolving Biomarker for Immunotherapy | Tumor Mutational Burden: A Continually Evolving Biomarker for Immunotherapy
Dan Brudzewsky, PhD
Senior Field Applications Scientist - UK & Nordics
Travis Yates, PhD
Field Applications Scientist
Tumor Mutational Burden: A Continually Evo... |
| Sep 10, 2020 | MiNA raises $30M to take small activating RNA into phase 2 | MiNA Therapeutics has raised £23 million ($30 million) to advance a pipeline of small activating RNAs (saRNAs) aimed at previously undruggable targets. The series A round will enable MiNA to move lead drug MTL-CEBPA into a phase 2 liver can... |
| Sep 10, 2020 | MiNA raises $30M to take small activating RNA into phase 2 | MiNA Therapeutics has raised £23 million ($30 million) to advance a pipeline of small activating RNAs (saRNAs) aimed at previously undruggable targets. The series A round will enable MiNA to move lead drug MTL-CEBPA into a phase 2 liver can... |
| Jan 22, 2020 | Health care needs AI. It also needs the human touch | As friends who work as pediatricians, we’ve had several conversations recently about artificial intelligence and its growing role in medicine. Machine learning and computer algorithms, it seems, are on the cusp of changing the medical profe... |